Alterity Therapeutics
Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.
Short position
Alterity Therapeutics (ASX:ATH) has 0.02% of its shares on issue reported as short positions as of 5 Oct 2026, or about 45,003 shares. Over the past 30 days that figure has fallen 0.09 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.18% in January 2024. ATH is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Alterity Therapeutics (ATH) company profile
Profile, insiders and operations
Company
AI-generated research profile of Alterity Therapeutics
ATH intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links